Wind, Sven <br/><br/>
Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.  [electronic resource] 

 -  Clinical pharmacokinetics  Dec 2013 
 - 1101-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1179-1926 
<br/><br/><label>Standard No.: </label>10.1007/s40262-013-0091-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Afatinib<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--blood<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--blood<br/>Protein Kinase Inhibitors--blood<br/>Quinazolines--blood<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Young Adult